The central offices and administrative staff of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) will house the Administrative Core. The Administrative Core will provide central administrative support to the Vanderbilt NCDDG. This includes financial management of the NCDDG, including grants management, progress reports, personnel appointments, service contracts, and supply acquisition. In addition, one ofthe most critical functions ofthe administrative core will be managing and ensuring effective communication between each of the organizational units within the NCDDG and with NIH. This includes managing capabilities for data sharing, organization for all NCDDG meetings, travel arrangements for face to face meetings with External Advisory Board and NIH staff. The administrative core will also coordinate practical aspects of program, including transfer of compounds and will monitor and manage regulatory compliance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19MH097056-01A1
Application #
8585979
Study Section
Special Emphasis Panel (ZMH1-ERB-C (05))
Project Start
Project End
Budget Start
2013-01-08
Budget End
2013-11-30
Support Year
1
Fiscal Year
2013
Total Cost
$73,685
Indirect Cost
$26,451
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Cho, Hyekyung P; Engers, Darren W; Venable, Daryl F et al. (2014) A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors. ACS Chem Neurosci 5:597-610
Cho, Hyekyung P; Garcia-Barrantes, Pedro M; Brogan, John T et al. (2014) Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics. ACS Chem Biol 9:2334-46
Conn, P Jeffrey; Lindsley, Craig W; Meiler, Jens et al. (2014) Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov 13:692-708
Bates, Brittney S; Rodriguez, Alice L; Felts, Andrew S et al. (2014) Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg Med Chem Lett 24:3307-14
Nickols, Hilary Highfield; Conn, P Jeffrey (2014) Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis 61:55-71
Amato, Russell J; Felts, Andrew S; Rodriguez, Alice L et al. (2013) Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. ACS Chem Neurosci 4:1217-28
Lovell, Kimberly M; Felts, Andrew S; Rodriguez, Alice L et al. (2013) N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Bioorg Med Chem Lett 23:3713-8